Balance Sheet

Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Interest Receivables Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Perspective Therapeutics (CATX) Deferred Taxes (2023 - 2024)

Perspective Therapeutics' Deferred Taxes history spans 2 years, with the latest figure at -$2.1 million for Q4 2024.

On a quarterly basis, Deferred Taxes fell 126.72% to -$2.1 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$2.1 million, a 20.9% increase, with the full-year FY2025 number at -$793000.0, up 62.18% from a year prior.
Deferred Taxes hit -$2.1 million in Q4 2024 for Perspective Therapeutics, down from $7.8 million in the prior quarter.
Over the last five years, Deferred Taxes for CATX hit a ceiling of $7.8 million in Q4 2023 and a floor of -$10.5 million in Q1 2023.